Video Experimental Relacionado
Updated: Sep 9, 2025
03:42
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
Published on: March 29, 2024
1.6K
Sulfonato de poliestireno de sodio y riesgo de insuficiencia cardíaca: un estudio comparativo con sulfonato de
Takashin Nakayama1, Hidehiro Kaneko2,3, Yuta Suzuki2,4
1Division of Endocrinology, Metabolism, and Nephrology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Nephrology (Carlton, Vic.)
|September 4, 2025
Resumen
El uso de sulfonato de poliestireno de sodio (SPS) está relacionado con un mayor riesgo de insuficiencia cardíaca (IC), especialmente en adultos mayores. Este estudio sugiere riesgos potenciales asociados con la carga de sodio inducida por SPS en el tratamiento de la hipercalemia.
Área de la Ciencia:
- Cardiología
- Nefrología
- Farmacología
Sus antecedentes:
- El sulfonato de poliestireno de sodio (SPS) es un tratamiento común para la hipercalemia.
- Existen preocupaciones con respecto a la carga de sodio asociada con el SPS.
- El sulfonato de poliestireno de calcio (CPS) es un aglutinante alternativo para el potasio.
Objetivo del estudio:
- Evaluar la asociación entre el inicio de la SPS y la insuficiencia cardíaca (IC).
- Comparar el riesgo de HF en pacientes tratados con SPS versus CPS.
- Investigar el impacto de la carga de sodio inducida por SPS en la incidencia de HF.
Principales métodos:
- Estudio retrospectivo basado en una base de datos nacional de reclamaciones (abril de 2014 - agosto de 2023).
- Inclusión de pacientes a los que se les haya recetado SPS o CPS.
- Comparación de la incidencia de HF utilizando la probabilidad inversa de ponderación del tratamiento (IPTW) basada en las puntuaciones de propensión.
Principales resultados:
- Se analizaron 3481 pacientes; 478 recibieron SPS y 3003 recibieron CPS.
- El uso de SPS se asoció con un mayor riesgo de desarrollar HF (HR 1,24; IC del 95% 1,00-1,53).
- La asociación fue más pronunciada en individuos de ≥78 años.
Conclusiones:
- Los datos del mundo real indican que el uso de SPS aumenta la probabilidad de desarrollar HF.
- La carga de sodio inducida por SPS puede contribuir al riesgo de HF.
- Se requiere una mayor investigación del perfil de seguridad de SPS, especialmente en pacientes de edad avanzada.
Palabras clave:
Sulfonato de poliestireno de calcioinsuficiencia cardíacahipercalemia, por ejemploSulfonato de poliestireno de sodioMás Videos Relacionados
Videos de Conceptos Relacionados
01:22Heart Failure Drugs: Diuretics
483
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
483
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:29Heart Failure II: Pathophysiology
33
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
33
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:22Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
01:22Heart Failure Drugs: β-Blockers
434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434